CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL)
has announced that allied contract manufacturer DSM Biologics has signed
a PER.C6 research license agreement with the Japanese . . .
TB ALLIANCE/GLAXOSMITHKLINE TO DEVELOP TB THERAPIES.
The Global Alliance for TB Drug Development (TB Alliance) and
GlaxoSmithKline (FTSE/NYSE: GSK) are pursuing a joint drug discovery
program to improve the treatment of tuberculosis (TB). The . . .
U.S. BIODEFENSE/UCL BIOMEDICA GET OPTION TO LICENSE
PATENT.
U.S. BioDefense (OTCBB:UBDE), City of Industry, has signed a 90 day
option to license European Patent Application No. 02743434.9, and U.S.
patent application 10/483,190 entitled "Liver cell . . .
CRYPTOME GETS OPTION FOR ANTI-INFLAMMATORY DRUG LICENSE.
Cryptome Pharmaceuticals Ltd, Melbourne, Australia, (ASX:CRP) has
signed an agreement with the University of Virginia giving the company
sole option to an exclusive license over a novel class . . .
OCTOPLUS\BIOLEX DEVELOPING LOCTERON.
OctoPlus, a drug delivery and development company and Biolex, Inc.,
a protein therapeutics company, have entered into collaboration for
co-development of a controlled release formulation of . . .
TOPICAL TRIAL OF MELANOTAN GETS UK REGULATORY APPROVAL.
EpiTan Limited (ASX: EPT, ADR: EPTNY, XETRA: UR9), Melbourne,
Australia has announced that approval has been obtained from the
UK's regulatory agency - The Medicines and Healthcare . . .
ARGENTA/NOVARTIS SIGN TWO-YEAR DRUG DISCOVERY PACT.
Argenta Discovery Ltd, Harlow, UK, a contract drug discovery and
respiratory drug development company, has entered into a two-year drug
discovery collaboration with Novartis. Under the terms of the . . .
AVEXA IN-LICENSES PHASE II HIV DRUG FROM SHIRE.
Research and development biotechnology company Avexa Limited (ASX:
AVX) has in-licensed the Phase II HIV drug - SPD754 - from global
specialty pharmaceutical company Shire Pharmaceuticals Group plc . . .
IMUGENE RECEPTOR MIMIC TECHNOLOGY PATENT GRANTED IN U.S.
Imugene (ASX: IMU), Sydney, Australia, has been granted patent
protection for its Receptor Mimic Technology (RMT) in the United States
through to 2020. The RMT is the platform for existing and new . . .
BIOSIGNAL AWARDED $1.377 M FOR ANTI-BACTERIAL CONTACT
LENSES.
The Australian Government, via the AusIndustry START grant program,
has awarded Biosignal Limited, Sidney, a $1.377 million grant to develop
new anti-bacterial extended wear contact lenses using . . .
CANGENE COMPLETES MRP FOR WINRHO SDF APPROVAL IN 10
COUNTRIES.
Cangene has successfully completed the European Mutual Recognition
Procedure ("MRP") for the approval of WinRho(R)SDF in ten
European countries for use in preventing hemolytic disease of . . .
THERATECHNOLOGIES GETS US $12 MILLION FOR MACROFLUX.
Theratechnologies (TSX: TH), Montreal, has received US $12 million
(CAD $15 million) from ALZA Corporation of Mountain View, California
(ALZA) for its interest in co-development projects using . . .
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE
PACT.
GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30; NASDAQ:
GPCB) and Debiopharm S.A., the independent drug- development company
specializing in oncology, endocrinology and niche products, . . .
NOVADEL SELECTS INYX TO PRODUCE NITROGLYCERIN LINGUAL
SPRAY.
Inyx, Inc. (OTC Bulletin Board: IYXI), New York, a specialty
pharmaceutical company with a focus on niche drug delivery technologies
and products, has been selected by NovaDel Pharma Inc. . . .
ANTISENSE TO INITIATE "PROOF OF CONCEPT" STUDY OF
ATL1101.
Antisense Therapeutics Limited, Melbourne, Australia will conduct a
"proof of concept" study of ATL1101 in patients with
psoriasis. The study will take place in Adelaide, Australia under . . .
LORUS SIGNS VIRULIZIN SUPPLY PACT WITH BIOVECTRA.
Lorus Therapeutics Inc. (Lorus), Toronto, a biopharmaceutical
company specializing in the research, development and commercialization
of pharmaceutical products and technologies for the management . . .
LIBRACOL AVAILABLE AT SOME 500 ADDITIONAL OUTLETS.
Magistral Biotech Inc. (TSX Venture: MBS) Montreal, has announced
that Libracol(R) will be available at approximately 500 new sales
outlets, including some 400 additional Loblaws stores, located . . .
SOMAXON EXERCISES OPTION TO LICENSE NALMEFENE.
Biotie Therapies Corp. and Somaxon Pharmaceuticals, Inc. have
announced that Somaxon has exercised its option to license nalmefene in
North America. The companies signed a cooperation and option . . .
MERRIMACK COMPLETES ENROLLMENT FOR MM-093 PHASE IIA.
Merrimack Pharmaceuticals, Inc., Cambridge, Mass., has completed
enrollment for a Phase IIa pilot study in patients with rheumatoid
arthritis with its immunomodulatory drug candidate, MM-093, . . .
AVIAN INFLUENZA VACCINE TRIALS INITIATED IN AUSTRALIA.
CSIRO Livestock Industries has developed an experimental vaccine to
protect chickens from the deadly H5N1 strain of avian influenza (bird
flu).
The trial vaccine utilizes Imugene Limited's . . .
|
|